FIELD: medicine.
SUBSTANCE: pharmaceutical oral dosage form contains a mixture treated in a melt and consisting of one active ingredient which represents a solid dispersion, at least one pharmaceutically acceptable polymer and a solubilising composition containing at least one tocopheryl-containing compound and at least one propylene glycol monofatty acid ester or a mixture of propylene glycol mono- and difatty acid esters. The active ingredient (ingredients) may be presented by a HIV protease inhibitor. The invention also refers to a method for preparing said pharmaceutical form which consists in preparing a homogenous melt of said active ingredient, said pharmaceutically acceptable polymer, and said solubilising composition, and making the melt to harden to form a solid disperse product.
EFFECT: solubilising composition provides higher biological availability of the active ingredient after the oral introduction.
Title | Year | Author | Number |
---|---|---|---|
PHARMACEUTICAL DOSED FORM, CONTAINING POLYMER CARRIER COMPOSITION | 2009 |
|
RU2519679C9 |
PHARMACEUTICAL COMPOSITION FOR HIV INFECTION TREATMENT | 2016 |
|
RU2619840C1 |
PHARMACEUTICAL COMPOSITION FOR TREATING HIV INFECTION, METHOD FOR PREPARING IT, AND METHOD OF TREATING | 2012 |
|
RU2505286C1 |
SOLID PHARMACEUTICAL COMPOSITION FOR MANUFACTURING ORAL ANTIRETROVIRAL THERAPEUTIC AGENT | 2020 |
|
RU2760129C1 |
PHARMACEUTICAL COMPOSITION HAVING ANTI-HIV INFECTION ACTIVITY | 2017 |
|
RU2659693C1 |
PHARMACEUTICAL COMPOSITION FOR TREATING HIV-INFECTION, METHOD FOR PREPARING AND METHOD OF USING | 2013 |
|
RU2543322C1 |
PHARMACEUTICAL DRUG FORM OF TYROSINE KINASE INHIBITOR FOR PERORAL INTRODUCTION | 2007 |
|
RU2468788C2 |
COMPOSITION AND DOSAGE FORM CONTAINING SOLID OR SEMISOLID MATRIX | 2006 |
|
RU2423997C9 |
METHOD FOR APPLICATION OF COPOLYMER OF DIMETHYLAMINOETHYLMETHACRYLATE, BUTYLMETHACRYLATE AND METHYL METHACRYLATE TO INCREASE SOLUBILITY AND/OR BIOAVAILABILITY OF ANTIRETROVIRAL ACTIVE PHARMACEUTICAL SUBSTANCE IN MANUFACTURE OF SOLID DISPERSION ON GRANULAR CARRIER | 2020 |
|
RU2759547C1 |
SOLID PHARMACEUTICAL COMPOSITION FOR MANUFACTURE OF ORAL THERAPEUTIC AGENT FOR PREVENTION AND/OR TREATMENT OF HIV INFECTION | 2021 |
|
RU2759544C1 |
Authors
Dates
2012-12-20—Published
2007-07-17—Filed